Program to up access to combo malaria therapy successful

November 1, 2012
Program to up access to combo malaria therapy successful
Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria has improved the availability, price, and market share of QAACTs, according to a study published online Oct. 31 in The Lancet.

(HealthDay)—Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria (AMFm) has improved the availability, price, and market share of QAACTs, according to a study published online Oct. 31 in The Lancet.

Sarah Tougher, M.D.E., from the London School of Hygiene and Tropical Medicine, and colleagues conducted nationally representative baseline and end point surveys of public and private sector outlets that stock antimalarial therapies to examine the effect of AMFm on QAACT price, availability, and six to 15 months after delivery of subsidized artemisinin-based combination therapies in seven countries (Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania [including Zanzibar]).

The researchers found that, with the exception of Niger and Madagascar, in all other pilots there were large increases in the availability of QAACT and in market share. These were mainly driven by changes in the private for-profit sector. In six pilots, large falls were seen in the median price for QAACTs per adult equivalent dose in the private for-profit sector. In Nigeria and Zanzibar, where the market share of oral artemisinin monotherapies was more than 5 percent at baseline, a decrease was observed.

"In summary, our evaluation has shown that subsidies applied to manufacturer price, when partnered with supporting interventions such as communications campaigns, can be an effective mechanism to rapidly improve the availability, price, and market share of QAACTs, particularly in the private for-," the authors write.

Explore further: New technologies gearing up to meet rising demand for vital malaria drugs

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

New fund promises low-cost malaria treatment

April 19, 2009

(AP) -- A $225 million fund to provide low-price anti-malaria medicine around the world was launched in the Norwegian capital Friday to fight a disease that kills 2,000 children a day.

Bad malaria pills in Africa raise resistance fears

February 8, 2010

(AP) -- High rates of the most effective type of malaria-fighting drugs sold in three African countries are poor quality - including nearly half the pills sampled in Senegal - raising fears of increased drug resistance that ...

Recommended for you

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

Team discovers how Zika virus causes fetal brain damage

August 24, 2016

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.